Adventrx Pharmac. Heisses Eisen ?

RELATED NEWS


Adventrx Pharma Reports Addl. Pre-Clinical Data For ANX-514


Adventrx Pharma Q3 Net Loss Narrows - Quick Facts


ADVENTRX To Stay Listed On AMEX, To Submit NDA For Cancer Drug By Year End - Update


ADVENTRX Pharma Issues Business Update Following Recent Financing Activity - Quick Facts


Adventrx Pharma Completes Registered Direct Offering Of About $11.3 Mln - Quick Facts
(RTTNews) - Within the next few days, Adventrx Pharmaceuticals Inc. (ANX: News ) is expected to submit its New Drug Application for ANX-530, a novel emulsion formulation of chemotherapy drug Navelbine (vinorelbine). If submitted, the filing will mark the first NDA submission for Adventrx' drug.

Navelbine, a branded formulation of vinorelbine, is approved in the U.S. to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer. According to the company, Navelbine, which, despite being a generic product for a number of years, still sells in excess of $200 million a year world-wide. Adventrx is planning to seek approval of ANX-530 for the same indications as Navelbine.

Adventrx has yet another late-stage product candidate ANX-514 (docetaxel emulsion for injection), a reformulation of the blockbuster chemotherapeutic agent, Taxotere.

Incorporated under the name Victoria Enterprises, Inc. in December 1995, the company began operations in 1996. The name was subsequently changed to "BioQuest, Inc." then to "Biokeys Pharmaceuticals, Inc." and finally to "ADVENTRX Pharmaceuticals, Inc." in May 2003. The company's common stock trades on the American Stock Exchange (Amex).

The company has incurred annual net losses since inception and has not generated any revenue from product sales to date. As mentioned earlier, the NDA for ANX-530 will be the first for the company if it is successfully filed.

As of September 30, 2009, the company had cash and cash equivalents of $3.2 million and in October raised $6 million from equity financing. The company, which has zero debt, believes that its cash on hand will be sufficient to permit it to continue operations through 2010.

ANX, which has been trading in the range of $0.07-$0.25 over the past twelve months, closed Friday's trading at $0.19.

www.rttnews.com/...spx?Id=1162047&Category=Breaking%20News

zwischen 2-5 Dollar alles dabei.

Man rechnet mit baldiger NEWS der NDA oder einem BUYOUT.

Das Volumen spricht eindeutig für sich das hier noch wesentlich mehr drin ist.

Was glaubt Ihr wieviele gestern und heute auch noch short gegangen sind.Sollten hier wirklich NEWS kommen knallt es hier dafür werden die Shorties dann schon sorgen.

  09:29:15     0,315     1.350    49.750§
  09:27:11     0,315     3.600    48.400§
  09:24:10      0,31     3.000    44.800§
  09:21:00      0,31     1.500    41.800§
  09:16:15      0,31    23.300    40.300§
  09:08:52     0,309     4.000    17.000§
  09:08:08     0,309    11.000    13.000§
  09:05:30     0,308     2.000§2.000

die Aktie befindet sich im stark überverkauften Bereich. Vielleicht mit ner kleinen Posi rein, könnte noch deutlich billiger werden...........könnte!!!!

Du hast geschrieben #3 :    

Was glaubt Ihr wieviele gestern und heute auch noch short gegangen sind.Sollten hier wirklich NEWS kommen knallt es hier dafür werden die Shorties dann schon sorgen.

 

Das ist doch wohl ein Witz.Es sind gerade mal knapp über 500 000 short

www.shortsqueeze.com/?symbol=anx&submit=Short+Quote%99

bei durchschnittlichen Umsätzen von 17,88 Mio Stück

www.google.com/finance?q=AMEX%3AANX

doch vom Dezember !?

04.01.2010 12:04
www.finanznachrichten.de/...x-530-new-drug-application-008.htm

ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application

SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).

"I congratulate our development team for achieving this important milestone on schedule in December, as planned. ANX-530 has the potential to offer important benefits to cancer patients, and we look forward to working with FDA towards its approval," said Brian M. Culley, Principal Executive Officer of ADVENTRX. "The ANX-530 NDA submission is a key step in our strategy to create valuable products that improve the performance of currently approved drugs."

The Company is seeking approval of ANX-530 for the same indications as Navelbine®, a branded formulation of vinorelbine, including non-small cell lung cancer. ADVENTRX submitted the NDA as a 505(b)(2) application, which relies in part on the FDA's findings of safety and effectiveness of a reference drug. The Company's 505(b)(2) NDA submission includes data from one clinical bioequivalence study designed to assess the pharmacokinetic equivalence of ANX 530 and Navelbine, the reference drug.

ANX-530 is ADVENTRX's proprietary emulsion formulation of vinorelbine. Vinorelbine is a vesicant and venous irritant, and these adverse effects can limit its tolerability. ANX-530 was designed to be bioequivalent to the reference drug while reducing the incidence and severity of vein irritation associated with intravenous delivery of the drug. In a clinical bioequivalence study, ANX 530 and the reference drug were determined to be bioequivalent.

ADVENTRX acquired ANX-530 in 2006 and retains exclusive worldwide rights to ANX-530, other than in China, Hong Kong, Macau and Taiwan.

...(weiter siehe LINK)

Monday, January 04, 2010
www.foxbusiness.com/story/markets/...-lucrative-oncology-drug/

ADENTRX set to move in on GlaxoSmithKline's lucrative oncology drug

realtime.bigcharts.com/...tyle=2003&size=1&mocktick=1" style="max-width:560px" />

bigcharts.marketwatch.com/charts/...p;rand=732&mocktick=1" style="max-width:560px" />

ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13
Date : 01/06/2010 @ 8:00AM
Source : PR Newswire
Stock : (ANX)
Quote :  0.29  0.0 (0.00%) @ 8:11AM

ih.advfn.com/...783669&article=40987947&symbol=A%5EANX

San Diego based ADVENTRX is subject of takeover rumors
1/6/2010 (BAYSTREET NEWSWIRE)

Shares of ADVENTRX (AMEX:ANX) began to bounce off session lows amid news that the company has become the subject of takeover rumors.

Even though ADVENTRX is an early stage oncology company it counts Carl Icahn's Ichan Capital Management, Renaissance Technologies, UBS AG, the Bank of New York Mellon and Barclay's Global Investors among its top institutional holders. The company recently submitted a long awaited New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).

The company's focus has been to create improved equivalent Oncology pharmaceutical products. Its lead product candidates, ANX-530 and ANX-514, are emulsion formulations of marketed chemotherapy drugs. Investors had taken shares to new highs in recent sessions before ADVENTRX announced that it had signed agreements to purchase shares of its Series E convertible preferred stock, representing gross proceeds of approximately $19,000,000. It is believed the company plans to use the majority of the proceeds from its latest offering to fund its operations during the FDA review period of the ANX-530 NDA.

ADVENTRX submitted their NDA as a 505(b)(2) application, which relies in part on the FDA's findings of safety and effectiveness of a reference drug. That maneuever and similar planned ones  offers high profits and lower risks for ADVENTRX, but it does threaten to take market share away from several bigger pharmaceutical companies, including GlaxoSmithKline.

Brian M. Culley, Principal Executive Officer of ADVENTRX said last week in a prepared statement:  "The ANX-530 NDA submission is a key step in our strategy to create valuable products that improve the performance of currently approved drugs."


Calls to Mr. Culley were not returned, but he is expected to be in attendance at next week's OneMedForum Finance Conference in San Francisco next week.

i127.photobucket.com/albums/p138/TrickyZ33/CowbellXtreme2.gif" style="max-width:560px" />

www.nasdaq.com/aspxcontent/...p;selected=ANX&mkttype=AFTER

Vielleicht habt ihr morgen früh noch ne chance billig reinzukommen....
Viel Chatter um Takeover/buyout/shortsqueeze und das hier ist keine Schrottfirma leute !

Biin mit an Bord...Habe mir ein kleines Sortiment ins Depot gelegt.

GAZILLIONEN BASHER AUF YAHOOO GERADE !!!!
Warum ??? (Short cover + noch billig rein wollen imo)

MOMO time...lol !
Hol die Kuhglocke raus..ANX ist heute auf allen RADARS...

was wäre denn ein angemessender Übernahmepreis ?
für dieses Unternehmen, danke vorab schon mal.

sind nur Gerüchte aber die Firma hat noch nichts herausgebracht was dagegen spricht.
Jemand hat eine Fake PR herausgebracht mit der Aussage des CEO's dass es nicht stimmt usw... grosse Manipulation von was weiss ich wem.
Gut= viele Basher (warscheinlich shorts oder sogar bezahlte Basher der Firma welche evtl übernimmt ?????)
Egal..ANX müsste so oder so viel mehr wert sein , haben gerade ein NDA gefiled und bald ist eine Konferenz ich glaube am 13. Januar....
Ich denke das ding wird heute und morgen viel MOMO haben...
Preis bei Übernahme keine Ahnung...

messages.finance.yahoo.com/...=73354&tof=5&frt=1#73354

20 GOOD things about ANX

07.01.2010 22:18
www.finanznachrichten.de/...unces-closing-of-financing-008.htm

ADVENTRX Pharmaceuticals Announces Closing of Financing

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has completed the previously announced sale of shares of its Series E convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ADVENTRX of approximately $19 million. ADVENTRX plans to use the net proceeds from the offering to fund activities relating to the commercial launch of ANX-530, including acquiring or developing sales, marketing and distribution capabilities and the associated regulatory compliance infrastructure, and to continue the development of ANX-514 in the United States, and for general corporate purposes.

The convertible preferred stock is convertible into shares of ADVENTRX's common stock at the option of the investors at a conversion price of $0.38115 per share and will accrue a 3.73344597664961% cumulative dividend until January 7, 2015. If the convertible preferred stock is converted at any time prior to January 7, 2015, ADVENTRX will pay the holder an amount equal to the total dividend that would accrue on the convertible preferred stock from the conversion date through January 7, 2015, or $186.67 per $1,000 stated value of convertible preferred stock converted, less any dividend payments made with respect to the converted convertible preferred stock. Approximately $3.5 million of the gross proceeds will be placed in an escrow account, which amounts will be released to make the dividend and other payments described above.

The investors also will receive warrants to purchase an aggregate of 12,462,285 shares of ADVENTRX's common stock. The warrants will have an exercise price of $0.3499 per share and are exercisable at any time after the closing of the transaction and before the thirty (30) month anniversary of the initial exercise date.

The convertible preferred stock and warrants are being offered by ADVENTRX pursuant to effective registration statement(s) on Form S-3 filed with the Securities and Exchange Commission ("SEC"). A prospectus relating to the offering was filed with the SEC on January 4, 2010. Rodman&Renshaw, LLC, a wholly owned subsidiary of Rodman&Renshaw Capital Group, Inc. , acted as the exclusive placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained directly from Rodman&Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, NY 10020, or from the SEC's website at www.sec.gov/.

...(weiter siehe LINK)

"The Company's strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods."

To read the entire report visit: http://www.beaconequity.com/i/ANX

See what investors are saying about these stocks at penny stock forum.

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Beacon Equity

CONTACT: Beacon Equity Research Jeff Bishop (469)-252-3505 press@beaconequity.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

 

 

 

Technical Trading Overview for Adventrx Pharmaceuticals Inc. (ANX)

Submitted by BeaconEquity.com
Friday, 8 January 2010
www.beaconequity.com/...or-adventrx-pharmaceuticals-inc-anx-2/